Clinical Trial Update: Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of trastuzumab and interleukin-2 in metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HER2-positive Breast Cancer, Male Breast Cancer | Phase 2 | Status: COMPLETED